Eli Lilly and Co announced the comparative trial results: Zepbound's weight-loss effect is better than Novo Nordisk's Wegovy.

eli lilly and co announced on Wednesday that in a comparative trial, its weight loss drug Zepbound had a greater weight loss effect than the competitor novo-nordisk a/s's similar drug Wegovy; eli lilly is still evaluating the trial results, the company stated that it plans to publish them in a peer-reviewed journal and present them at medical conferences next year.

cls.cn30minutes ago

Better than Wegovy! eli lilly and co's weight loss drug Zepbound averaged a 20% weight loss over 72 weeks, with a 2.5% pre-market surge.

Participants using Wegovy from novo-nordisk a/s only experienced a 14% reduction. This result presents eli lilly and co with an opportunity to surpass, especially with the obesity drug market expected to reach 130 billion USD by the end of this decade.

wallstreetcn45minutes ago

Jim Cramer: This Energy Stock Is A 'Winner,' But Navitas Semiconductor Is 'Losing A Lot Of Money'

Benzinga08:06 ET

Update: Eli Lilly Says Its Zepbound Showed 47% 'Greater Relative Weight Loss' Against Wegovy in Phase 3b Trial

MT Newswires08:05 ET

Express News | Rondo Therapeutics Announces Collaboration With Lilly to Develop Novel Cd28 Bispecific Antibodies for Solid Tumors

Reuters08:04 ET

US Morning News Call | Stock Index Futures Climb on Positive Earnings, Focus Shifts to Upcoming Speech by Powell

Moomoo Breakfast US07:51 ET